USC study shows raloxifene may increase ovarian cancer growth rate

July 03, 2001

LAUSANNE, SWITZERLAND, July 3-- The drug raloxifene may increase the growth rate of ovarian cancer and its risk of recurrence, according to researchers from the Keck School of Medicine of the University of Southern California.

Speaking at the European Society of Human Reproduction and Embryology's annual meeting, David Tourgeman, M.D., assistant professor of obstetrics and gynecology at the Keck School, presented data on the effects of raloxifene both alone and in combination with estradiol on ovarian cancer cell lines in the laboratory.

Raloxifene is a selective estrogen receptor modulator (SERM) that has been approved in the United States for use in patients with osteoporosis but has also been looked at as a possible agent for women needing estrogen replacement therapy (ERT). Past research has shown that raloxifene actually has antiestrogenic effects in human breast cancer cells, making it a potentially safe ERT alternative for women who have had breast cancer. In addition, it doesn't seem to increase the risk of uterine cancer in postmenopausal women.

To date, however, not much work has been done on the drug's affects on ovarian cancer, despite the fact that ovarian cancer, too, is a hormone-driven disease, noted Tourgeman.

Along with Richard Paulson, M.D., Keck School professor of obstetrics and gynecology, and their USC colleagues, Tourgeman found that both raloxifene and estradiol stimulate cell growth in ovarian adenocarcinoma cells that carried estrogen receptors on their cell surface (ER+ cells)--and that the drugs' effects occur both when they are given independently and in combination. The cells were exposed to an amount of raloxifene equivalent to that which would be received by the usual 60 mg oral dose of the drug.

"To our knowledge, this is the first time that the effect of raloxifene on ovarian cell lines has been evaluated," said Tourgeman. He notes that there is an ongoing debate as to whether the presence of estrogen receptors on the tumor cells means that estrogen would necessarily cause an ovarian tumor to grow or reappear. Still, he says, "as up to 60 percent of epithelial ovarian cancers and a smaller percentage of anaplastic or recurrent ovarian cancers will be ER+, the most appropriate approach would be one of caution. In contrast to the clinical management of women with a history of breast cancer, raloxifene may not be a good alternative to ERT in women with ER+ ovarian cancer."

Both he and Paulson, however, stressed that this finding does not diminish the recognized benefits of ERT in general for strengthening bone, protecting the cardiovascular system and improving cognition.

That is why, Paulson says, "it would be premature to withhold all forms of ERT from patients with a history of ovarian cancer on the basis of these findings." He and Tourgeman intend to evaluate raloxifene in other cell types to see if it has similar effects. In addition, says Paulson, the hope is that this study will serve as an impetus to other researchers to undertake epidemiologic studies that would evaluate the possible association between raloxifene and ovarian cancer.
-end-
"Agonistic Effects of Raloxifene on the Growth of Ovarian Adenocarcinoma (OVCAR-3) Cells." D.E. Tourgeman, C.A. Amezcua, R. Boostanfar, F.Z. Stanczyk, J. Felix, R.J. Paulson.

University of Southern California

Related Breast Cancer Articles from Brightsurf:

Oncotarget: IGF2 expression in breast cancer tumors and in breast cancer cells
The Oncotarget authors propose that methylation of DVDMR represents a novel epigenetic biomarker that determines the levels of IGF2 protein expression in breast cancer.

Breast cancer: AI predicts which pre-malignant breast lesions will progress to advanced cancer
New research at Case Western Reserve University in Cleveland, Ohio, could help better determine which patients diagnosed with the pre-malignant breast cancer commonly as stage 0 are likely to progress to invasive breast cancer and therefore might benefit from additional therapy over and above surgery alone.

Partial breast irradiation effective treatment option for low-risk breast cancer
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center - Arthur G.

Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years
Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.

More clues revealed in link between normal breast changes and invasive breast cancer
A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process -- changes in mammary glands to accommodate breastfeeding -- uses a molecular process believed to contribute to survival of pre-malignant breast cells.

Breast tissue tumor suppressor PTEN: A potential Achilles heel for breast cancer cells
A highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report in Nature Communications that they have identified a novel pathway for connective tissue PTEN in breast cancer cell response to radiotherapy.

Computers equal radiologists in assessing breast density and associated breast cancer risk
Automated breast-density evaluation was just as accurate in predicting women's risk of breast cancer, found and not found by mammography, as subjective evaluation done by radiologists, in a study led by researchers at UC San Francisco and Mayo Clinic.

Blood test can effectively rule out breast cancer, regardless of breast density
A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue.

Study shows influence of surgeons on likelihood of removal of healthy breast after breast cancer dia
Attending surgeons can have a strong influence on whether a patient undergoes contralateral prophylactic mastectomy after a diagnosis of breast cancer, according to a study published by JAMA Surgery.

Young breast cancer patients undergoing breast conserving surgery see improved prognosis
A new analysis indicates that breast cancer prognoses have improved over time in young women treated with breast conserving surgery.

Read More: Breast Cancer News and Breast Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.